---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-013815"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-09-17T23:59:59+00:00"
generated_at: "2026-05-17T06:23:26.517118+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Dermata reports statistically significant Phase 3 XYNGARI acne data vs placebo at EADV 2025

## Summary
- IGA 2-point reduction + clear/almost clear at Week 12: 29.4% XYNGARI vs 15.2% placebo (p<0.001).
- Mean inflammatory lesion count change at Week 12: -16.8 XYNGARI vs -13.1 placebo (p<0.001).
- Percent change in non-inflammatory lesions at Week 12: 48.3% XYNGARI vs 34.7% placebo (p<0.001).
- All secondary endpoints (IGA, inflammatory, non-inflammatory) statistically significant at Weeks 4, 8, and 12.
- Data presented at European Academy of Dermatology and Venereology Congress 2025 from ongoing Phase 3 STAR-1 trial.

## SEC filing metadata
- accession: 0001493152-25-013815
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000149315225013815/0001493152-25-013815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000149315225013815/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-013815
- JSON: https://secwatch.observer/filing/0001493152-25-013815.json
- Plain text: https://secwatch.observer/filing/0001493152-25-013815.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.